Icosavax Inc

NASDAQ ICVX

Download Data

Icosavax Inc Return on Total Capital (ROTC) 5 year CAGR for the year ending September 20, 2024

Icosavax Inc Return on Total Capital (ROTC) 5 year CAGR is NA for the year ending September 20, 2024. Return on total capital measures the profitability of a company relative to its total capital, which includes total debt and shareholders' equity. It is calculated by dividing the net income by the sum of total debt and shareholders' equity. This ratio provides insights into the return generated for each unit of total capital invested in the company. A higher return on total capital indicates better profitability and efficient utilization of both debt and equity capital. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ICVX

Icosavax Inc

CEO Mr. Adam K. Simpson
IPO Date July 29, 2021
Location United States
Headquarters 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees 60
Sector Healthcare
Industry Biotechnology
Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

FRLN

Freeline Therapeutics Holdings Plc

NA

NA

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email